[1] |
KE Xiuqin, HAI Xuewu.
433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
|
[2] |
ZHENG Sili, ZHANG Xiaoqing.
133 Cases of Adverse Drug Reactions in Female Patients
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 654-658.
|
[3] |
WANG Hao, MA Jinfu, MA Rui, LI Xiaogang, ZHAO Qiang, ZHANG Xian.
One Case of Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium for Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 686-688.
|
[4] |
MEI Liping, BAI Fuchen, YU Jie, ZHANG Chunjie, WANG Yajun, AN Limei.
Determinants of Blood Drug Concentration / Dose Ratio of Antipsychotics
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 424-428.
|
[5] |
ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning.
Words of Warning and Preventive Measures in Labels of Antidepressants
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.
|
[6] |
ZHOU Kun, MA Liang, LI Zhaofeng, CAO Bing, GU Hongwei, LIU Qian.
Usage of Nerve-Calming Chinese Herbal Patent Medicines in a Mental Health Center
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 211-216.
|
[7] |
NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan.
Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.
|
[8] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[9] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|
[10] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|
[11] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[12] |
LI Wenpeng, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Applications and progress of methods for estimating opioids requirements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 519-523.
|
[13] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[14] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[15] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|